Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Bell

Showing results (981-990 of 1,019) with videos related to

Pageof 102
Sort By:
JCO Oncology Practice|December 14, 2021
Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator NetworkViswatej Avutu, Varun Monga, Nupur Mittal, et al.
The American Journal of Gastroenterology|May 11, 2011
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregiversJasmohan S Bajaj, James B Wade, Douglas P Gibson, et al.
Physical Review Letters|April 7, 2010
On demand triggering of edge localized instabilities using external nonaxisymmetric magnetic perturbations in toroidal plasmasJ M Canik, R Maingi, T E Evans, et al.
Nature Immunology|February 24, 2015
The RNA-binding protein HuR is essential for the B cell antibody responseManuel D Diaz-Muñoz, Sarah E Bell, Kirsten Fairfax, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Science (New York, N.Y.)|August 28, 2025
Architecture of the UBR4 complex, a giant E4 ligase central to eukaryotic protein quality controlDaniel B Grabarczyk, Julian F Ehrmann, Paul Murphy, et al.
Journal of Exposure Science & Environmental Epidemiology|August 4, 2016
Exposure science in an age of rapidly changing climate: challenges and opportunitiesJudy S LaKind, Jonathan Overpeck, Patrick N Breysse, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Pageof 102

Showing results (981-990 of 1,019) with videos related to

Sort By:
Pageof 102
JCO Oncology Practice|December 14, 2021
Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator NetworkViswatej Avutu, Varun Monga, Nupur Mittal, et al.
The American Journal of Gastroenterology|May 11, 2011
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregiversJasmohan S Bajaj, James B Wade, Douglas P Gibson, et al.
Physical Review Letters|April 7, 2010
On demand triggering of edge localized instabilities using external nonaxisymmetric magnetic perturbations in toroidal plasmasJ M Canik, R Maingi, T E Evans, et al.
Nature Immunology|February 24, 2015
The RNA-binding protein HuR is essential for the B cell antibody responseManuel D Diaz-Muñoz, Sarah E Bell, Kirsten Fairfax, et al.
Leukemia|August 13, 2011
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trialK D Boyd, F M Ross, L Chiecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX StudyAndy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Science (New York, N.Y.)|August 28, 2025
Architecture of the UBR4 complex, a giant E4 ligase central to eukaryotic protein quality controlDaniel B Grabarczyk, Julian F Ehrmann, Paul Murphy, et al.
Journal of Exposure Science & Environmental Epidemiology|August 4, 2016
Exposure science in an age of rapidly changing climate: challenges and opportunitiesJudy S LaKind, Jonathan Overpeck, Patrick N Breysse, et al.
Blood|October 25, 2011
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysisGareth J Morgan, Walter M Gregory, Faith E Davies, et al.
Haematologica|November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial resultsGareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Pageof 102